ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jan 12, 2022 10:25 JST
Source:
Apollomics, Inc.
Apollomics Inc. to Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022
English and Chinese Sessions to be Held to Accommodate Multiple Time Zones
Foster City, CA, Shanghai and Hangzhou, China, Jan 12, 2022 - (ACN Newswire) - Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the management team will host two upcoming webcasts to accommodate participants from the U.S. and China. Co-Founder, Chairman and Chief Executive Officer, Guo-Liang Yu, PhD, will be joined by Sanjeev Redkar, PhD, Co-Founder and President, K. Peony Yu, M.D., Chief Medical Officer, and Wilson W. Cheung, CPA, Chief Financial Officer, to provide a strategic overview and an update on the Company's pipeline programs.
Session Dates/Times:
Session U.S. Pacific U.S. Eastern China Europe
English January 26th 11:00 a.m. January 26th 2:00 p.m. January 27th3:00 a.m. January 26th 8:00 p.m.
Chinese January 26th 7:00 p.m. January 26th 10:00 p.m. January 27th 11:00 a.m. January 27th 4:00 a.m.
All are invited to listen to the event and view the presentation via webcast on the Apollomics website under the News/Events section: Events and Presentations (
https://www.apollomicsinc.com/press-releases/events-presentations/
). An archive of the webcast will be available for three months.
About Apollomics Inc.
Apollomics Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting and immuno-oncology agents. The Company's product pipeline has several programs at different stages of development, including novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Apollomics has operating entities in Foster City, California, USA, Hangzhou and Shanghai, China. For more information, please visit www.apollomicsinc.com.
Contact Information:
Investor Contact:
Wilson W. Cheung
Chief Financial Officer
(650) 209-4436
wcheung@apollomicsinc.com
U.S. Media Contact:
Remy Bernarda
Corporate Communications
(415) 203-6386
remy.bernarda@apollomicsinc.com
China Media Contact:
Porda Havas International Finance Communications Group
Kelly Fung
General Manager
(852) 3150 6763
kelly.fung@pordahavas.com
Source: Apollomics, Inc.
Sectors: Clinical Trials
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
International Land Alliance Unveils New Revenue Model Featuring 100 Rental Homes in Cabo Oasis
Jul 16, 2025 22:00 JST
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
Jul 16, 2025 14:50 JST
New Trains for Singapore's Sengkang-Punggol LRT Begin Commercial Operation
Jul 16, 2025 14:34 JST
AUG East Consortium and NEC to develop high-capacity submarine cable system across East Asia
Jul 16, 2025 14:00 JST
Anime Tokyo Station: Mobile Suit Gundam GQuuuuuuX -Beginning- Special Exhibition - New Designs Added for Admission Bonus Illustration Cards
Jul 16, 2025 11:00 JST
Fujitsu Data Intelligence PaaS enhances Mazda's data-utilization and decision-making
Jul 16, 2025 10:30 JST
Fujitsu and Acer Medical trial AI service that assesses future disease risk in elderly patients through gait pattern abnormality detection
Jul 16, 2025 10:20 JST
All Nippon Airways and Hitachi Unveil Japan's First Airline "Operations Brain" System, Enabling Rapid, Optimal Flight Schedule Revisions During Disruptions
Jul 15, 2025 12:00 JST
Fujitsu's AI-powered supply chain solution selected as transformative example of applied-AI technology by World Economic Forum
Jul 14, 2025 10:30 JST
"URECE" (Dotinurad) Launched in China as a treatment for Gout
Jul 14, 2025 10:20 JST
Mitsubishi Motors Added to FTSE4Good Index Series, FTSE Blossom Japan Index and FTSE Blossom Japan Sector Relative Index for Consecutive Years
Jul 11, 2025 16:28 JST
All-New MAZDA CX-5 Debuts in Europe
Jul 10, 2025 18:56 JST
Sharp Signs Official Partnership with Tottenham Hotspur FC Pre-season Tour 2025 with Its AQUOS Brand
Jul 10, 2025 17:30 JST
Hitachi develops "Metaverse Platform for Nuclear Power Plants" to enhance efficiency in construction and maintenance operations
Jul 09, 2025 19:02 JST
"Development of Integrated Simulation Platform for Sustainable and Competitive Maritime Industry" has been selected as a R&D project under K Program
Jul 08, 2025 20:30 JST
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment
Jul 08, 2025 09:31 JST
MHI Awarded Contract for Basic Design of Japan's Largest CO2 Capture Plant at Hokkaido Electric Power's Tomato-Atsuma Power Station
Jul 07, 2025 11:15 JST
Fujitsu's high-precision skeleton recognition AI adopted to enhance figure skating athlete training
Jul 05, 2025 13:40 JST
DENSO Acquires Axia Vegetable Seeds to Realize Sustainable Agriculture
Jul 04, 2025 16:20 JST
MHIET Launches 450kW Gas Cogeneration System Capable of Hydrogen Co-Firing
Jul 04, 2025 15:13 JST
More Latest Release >>
Related Release
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
March 30 2023 20:29 JST
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer
July 26 2022 09:17 JST
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group
January 04 2022 10:10 JST
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
November 22 2021 10:40 JST
Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial
October 01 2021 10:00 JST
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102
August 10 2021 11:53 JST
APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH
May 20 2021 13:36 JST
Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer
March 09 2021 10:35 JST
Apollomics, Inc Announces Enrollment of First Patient in Phase 1 Clinical Trial of APL-106 (uproleselan injection) in China
March 04 2021 11:30 JST
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
February 12 2021 13:00 JST
More Press release >>